CD274 and ovarian cancer: At the moment, several clinical trials have been conducted on small-scale populations of patients for ovarian cancer, and they used the following molecules in their research: ipilimumab, tremelimumab, nivolumab, pembrolizumab, and other anti-PDL-1 antibodies, such as BMS-936559, MEDI4736, MPDL33280A, and MSB0010718C (avelumab) [85].